PABPN1 CRISPR Activation Plasmid (h): sc-403802-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PABPN1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- PABPN1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by PABPN1 CRISPR Activation Plasmid (h) and PABPN1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PABPN1 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PABPN1 CRISPR Activation Plasmid (h) | sc-403802-ACT | 20 µg | $397.00 |
Human PABPN1 (poly(A) binding protein nuclear 1) is a ubiquitously expressed nuclear RNA-binding protein that associates with the poly(A) tail to regulate mRNA 3′-end processing, polyadenylation, and transcript stability. By influencing poly(A) tail length control and RNA maturation, PABPN1 contributes to global gene expression programs and RNA metabolism within the nucleus. Dysregulation or mutation of PABPN1 perturbs RNA processing and proteostasis pathways and is linked to skeletal muscle pathology, most notably oculopharyngeal muscular dystrophy (OPMD). As a core component of post-transcriptional regulation, PABPN1 is widely studied in mechanisms of RNA quality control, nuclear RNA turnover, and stress-associated changes in mRNA processing.
PABPN1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PABPN1 expression without altering the underlying DNA sequence.
PABPN1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PABPN1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PABPN1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous PABPN1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PABPN1 locus and enabling the study of PABPN1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of PABPN1 pathway restoration in tumor cells with silenced or reduced PABPN1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.